Used in the development of immunotherapies targeting multiple myeloma. Binds specifically to SLAMF7 (CS1), a surface protein highly expressed on malignant plasma cells but limited in normal tissues, enabling targeted destruction of cancer cells. Supports antibody-dependent cellular cytotoxicity (ADCC) by engaging immune effector cells. Serves as a reference standard in bioassay development, potency testing, and quality control for biosimilars and biobetter antibodies. Facilitates pharmacokinetic and pharmacodynamic studies during preclinical and clinical development. Also employed in flow cytometry and immunohistochemistry for detection and quantification of SLAMF7 expression in patient samples.